XtalPi Reports First Full-Year Profit, Holds USD 1 Billion Cash

XtalPi posted its first full-year profit in 2025, with revenue of RMB 800 million and net profit of RMB 258 million.

A major U.S. pharma contract drove much of the growth, while the automated lab business emerged as a recurring revenue engine.

The company ended the year with more than RMB 7 billion in cash, giving it room to invest and expand.

XtalPi plans to focus on algorithms, lab capacity, selective clinical programs, new materials, and overseas growth.